Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $70.48
  • 50 Day Moving Average: $70.7765
  • 200 Day Moving Average: $74.7512
  • 52-Week Range: $65.38 - $103.10
  • Trailing P/E Ratio: 7.1011
  • Foreward P/E Ratio: 8.88
  • P/E Growth: -1.7100
  • Market Cap: $92.47B
  • Outstanding Shares: 1,310,000,000
  • Beta: 1.11
  • Net Margins: 44.43%
  • Return on Equity: 92.36%
  • Return on Assets: 29.22%
  • Debt-to-Equity Ratio: 1.53%
  • Current Ratio: 4.17%
  • Quick Ratio: 4.00%
Additional Links:
Companies Related to Gilead Sciences:

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 10 Hold Ratings, 16 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $86.38 (22.57% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
DateFirmActionRatingPrice TargetDetails
3/1/2017MizuhoLower Price Target$77.00View Rating Details
3/1/2017Credit Suisse GroupReiterated RatingBuy$79.00View Rating Details
2/16/2017Piper Jaffray CompaniesReiterated RatingOverweightView Rating Details
2/14/2017Stifel NicolausSet Price TargetBuy$87.00View Rating Details
2/14/2017J P Morgan Chase & CoSet Price TargetBuy$82.00View Rating Details
2/14/2017Berenberg BankSet Price TargetBuy$112.00 -> $78.00View Rating Details
2/14/2017Jefferies Group LLCReiterated RatingBuy$83.00View Rating Details
2/9/2017Barclays PLCReiterated RatingBuyView Rating Details
2/8/2017Leerink SwannSet Price TargetHold$91.00 -> $74.00View Rating Details
2/9/2017BMO Capital MarketsReiterated RatingHold$88.00 -> $75.00View Rating Details
2/8/2017RBC Capital MarketsLower Price Target$75.00View Rating Details
2/8/2017Needham & Company LLCReiterated RatingHoldView Rating Details
2/8/2017Robert W. BairdReiterated RatingOutperform$87.00View Rating Details
2/8/2017Citigroup Inc.DowngradeBuy -> Neutral$87.00 -> $76.00View Rating Details
2/8/2017Morgan StanleyLower Price TargetEqual Weight$85.00 -> $77.00View Rating Details
2/8/2017Wells Fargo & CoReiterated RatingMarket Perform$79.50 -> $65.50View Rating Details
2/6/2017Cowen and CompanySet Price TargetBuy$100.00View Rating Details
1/28/2017William BlairReiterated RatingOutperformView Rating Details
1/13/2017Goldman Sachs Group IncReiterated RatingHold$81.00View Rating Details
11/6/2016Maxim GroupReiterated RatingHoldView Rating Details
11/2/2016Royal Bank of CanadaLower Price TargetOutperform$95.00 -> $90.00View Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00View Rating Details
9/25/2016Bank of America CorpReiterated RatingNeutral$100.00View Rating Details
9/23/2016GabelliReiterated RatingBuyView Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00View Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details
5/4/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$120.00 -> $116.00View Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00View Rating Details
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details
(Data available from 3/1/2015 forward)


Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
Current Year EPS Consensus Estimate: $8.57 EPS
Next Year EPS Consensus Estimate: $7.94 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20162$3.03$3.25$3.14
Q3 20164$2.77$3.04$2.87
Q4 20163$1.14$2.62$2.06
Q1 20172$2.16$2.25$2.21
Q2 20172$2.05$2.14$2.10
Q3 20172$1.90$1.92$1.91
Q4 20172$1.78$1.82$1.80
(Data provided by Zacks Investment Research)


Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Annual Dividend:$1.88
Dividend Yield:2.67%
Payout Ratio:18.91% (Based on Trailing 12 Months of Earnings)
21.94% (Based on Current Year Consensus EPS Estimate)
23.68% (Based on Next Year Consensus EPS Estimate)

Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 74.19%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline logoAnalyst Activity – Credit Suisse Group Reiterates Buy on Gilead Sciences (NASDAQ:GILD) (NASDAQ:GILD) - March 1 at 12:17 PM
News IconTwin Capital Management Inc. Increases Position in Gilead Sciences, Inc. (GILD) (NASDAQ:GILD) - March 1 at 12:17 PM
News IconThe Case for and Against Gilead Sciences Inc. (GILD) (NASDAQ:GILD) - March 1 at 12:17 PM logoHow Gilead’s Revenue Trended in 2016 (NASDAQ:GILD) - March 1 at 12:17 PM logoHow Gilead’s HIV Drugs Portfolio Fared in 2016 (NASDAQ:GILD) - March 1 at 12:17 PM logoGilead Sciences: M&A to the Rescue? (NASDAQ:GILD) - March 1 at 12:17 PM logoGilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14 (NASDAQ:GILD) - February 28 at 5:34 PM logoMerck Restates 2016 Earnings, Takes $2.9B Charge (NASDAQ:GILD) - February 27 at 7:07 PM logoGILEAD SCIENCES INC Files SEC form 10-K, Annual Report (NASDAQ:GILD) - February 27 at 7:07 PM
News IconAnalytical and Technical Charts for Gilead Sciences Inc. (GILD) (NASDAQ:GILD) - February 25 at 5:15 PM
News IconGilead Sciences Inc. (GILD) Shouts Loudly With Its Technical Chart - NY Stock News (NASDAQ:GILD) - February 25 at 2:51 AM logoWhat I'm Doing With My Gilead Sciences Shares (NASDAQ:GILD) - February 24 at 6:42 PM
News IconTrading Notes on Gilead Sciences Inc. (NASDAQ:GILD): Active Stock Recap (NASDAQ:GILD) - February 24 at 6:42 PM logoGilead: No HCV? No Problem (NASDAQ:GILD) - February 24 at 10:57 AM
News IconAnalyst Sentiment Outlines Long Term Upside for Gilead Sciences Inc. (NASDAQ:GILD) (NASDAQ:GILD) - February 23 at 10:29 PM
News IconDividend Stock To Monitor: Gilead Sciences Inc. (GILD) (NASDAQ:GILD) - February 23 at 10:29 PM logoGilead Sciences, Inc. (NASDAQ:GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C (NASDAQ:GILD) - February 23 at 5:27 PM
News IconUndervalued Gilead Sciences – FCF/EV Yield 30%, Shareholder Yield 17% (NASDAQ:GILD) - February 23 at 5:27 PM logoBaby Boomers: Gilead’s New Hep C Target Group (GILD) (NASDAQ:GILD) - February 23 at 5:27 PM
News IconGilead Sciences Inc. (NASDAQ:GILD) Touching Most Active List (NASDAQ:GILD) - February 23 at 5:27 PM logoSolid Uptake of This Drug Could Drive Gilead’s 2017 Product Sales (NASDAQ:GILD) - February 23 at 5:27 PM logoBig Pharma Quietly Enlists Leading Professors to Justify $1,000-a-Day Drugs (NASDAQ:GILD) - February 23 at 5:27 PM logoThis Strategy Could Boost GILD’s HIV Franchise Revenue in 2017 (NASDAQ:GILD) - February 23 at 5:27 PM logoBaby Boomers: Gilead’s New Hep C Target Group (NASDAQ:GILD) - February 23 at 5:26 PM logoGilead Sciences, Inc. (GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C (NASDAQ:GILD) - February 23 at 5:26 PM logoAbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink (NASDAQ:GILD) - February 23 at 5:26 PM logoGilead's M&A Growth Strategies Becoming Increasingly Limited (NASDAQ:GILD) - February 22 at 10:43 PM
News IconBiotechnology: Gilead Sciences Inc. (NASDAQ:GILD) Position of the day (NASDAQ:GILD) - February 22 at 10:43 PM
News IconRecommendation Trends to See: Gilead SciencesA Inc. (GILD) (NASDAQ:GILD) - February 22 at 10:43 PM
News IconGilead Sciences Inc. (NASDAQ:GILD) shows monthly volitility of 1.78% (NASDAQ:GILD) - February 22 at 10:43 PM logoGilead Sciences Expects to Witness an Earnings Fall in 2017 (NASDAQ:GILD) - February 22 at 10:43 PM logoGilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs (NASDAQ:GILD) - February 22 at 5:41 PM logoGilead Sciences Raises Dividend by Double Digits (NASDAQ:GILD) - February 22 at 5:41 PM logo3 Things Gilead Sciences' CEO Just Said That You'll Want to Know (NASDAQ:GILD) - February 22 at 3:57 PM
News IconChecking Out the Technicals for Gilead Sciences Inc. (GILD) - The USA Commerce (NASDAQ:GILD) - February 22 at 12:07 PM logoWhat Could Vemlidy Mean For Gilead? - Gilead Sciences, Inc ... - Seeking Alpha (NASDAQ:GILD) - February 22 at 12:07 PM
News IconAnalytical Guide for Abbott Laboratories (ABT), Gilead Sciences Inc. (GILD) Stakeholders - The USA Commerce (NASDAQ:GILD) - February 22 at 12:07 PM
News IconSarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces $125 Deal with Gilead Sciences, Inc. (GILD) - StockNewsUnion (NASDAQ:GILD) - February 22 at 12:07 PM logoGilead Sciences, Inc. (GILD) Stock Has Caught a Cold - (NASDAQ:GILD) - February 22 at 12:07 PM logo[$$] Gilead Goes to the Head of the Line (NASDAQ:GILD) - February 22 at 12:07 PM logoOntario Becomes First Province To List EPCLUSA™ On Public Drug Plan To Treat All Six Genotypes Of Chronic Hepatitis C Infection (NASDAQ:GILD) - February 22 at 12:07 PM logoWhat Are Analysts’ Recommendations for Gilead Sciences in 2017? (NASDAQ:GILD) - February 22 at 12:07 PM logoGilead Goes to the Head of the Line (NASDAQ:GILD) - February 21 at 1:48 PM logoGilead Sciences, Inc. (GILD) Stock Has Caught a Cold (NASDAQ:GILD) - February 21 at 1:01 PM
News IconEquity Perception: Analyst's Indicator Review for Gilead Sciences Inc. (GILD), Starbucks Corporation (SBUX) - The USA Commerce (NASDAQ:GILD) - February 20 at 4:57 PM logoGilead Sells Anti-Addiction Drug to Amygdala (NASDAQ:GILD) - February 20 at 4:57 PM logoYour Burning Biotech Questions Answered (NASDAQ:GILD) - February 20 at 10:59 AM logoWhy Gilead Sciences Is a Buy (NASDAQ:GILD) - February 19 at 9:15 AM
News IconThe Technical Facts on Gilead Sciences Inc. (GILD) - The USA Commerce (NASDAQ:GILD) - February 18 at 12:26 PM logoGilead's HCV Guidance Wasn't Sandbagged - Seeking Alpha (NASDAQ:GILD) - February 18 at 12:26 PM


What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Tuesday, February 7th. Shareholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share on Thursday, March 30th. This represents a $2.08 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Tuesday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.47.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

27 brokerages have issued 1-year price targets for Gilead Sciences' shares. Their predictions range from $65.50 to $116.00. On average, they expect Gilead Sciences' share price to reach $86.38 in the next twelve months.

When will Gilead Sciences announce their earnings?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)
  • Jefferies Group LLC analysts commented, "Though expectations were relatively high going into the data, "sneak peek" at bic vs. dolu HTH ph.III HIV data at evening CROI press conference show GILD's integrase trending towards better efficacy vs. dolu-- explaining co's recent enthusiasm. Small study, but much needed good news for GILD and recall bictegravir will help maintain LT HIV franchise post-2025. Expect upside on increasing comfort on HIV franchise longevity given increasing dependence on HIV." (2/14/2017)
  • According to Zacks Investment Research, "Although Gilead’s fourth quarter results beat on both earnings and sales, the guidance for 2017 was disappointing. The HCV franchise continues to be under competitive and pricing pressure due to which the sales of Harvoni and Sovaldi have declined. Total HCV treatment starts in the U.S. were an estimated 231,000 in 2016, approximately 25,000 less than 2015. The company expects a further decline in patients starts in 2017. In addition, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. Shares of Gilead have underperformed the biotech industry in the past one year. On a positive note, Epclusa’s uptake has been encouraging while the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales." (2/13/2017)

  • Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)
  • Cowen and Company analysts commented, "Effective Jan. 1, the U.S. price of Atripla has been increased by 2.3%." (1/6/2017)

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.59%), FMR LLC (2.97%), Franklin Resources Inc. (1.09%), Temasek Holdings Private Ltd (1.06%), Renaissance Technologies LLC (0.40%) and AQR Capital Management LLC (0.32%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter, Richard James Whitley and Robin L Washington.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Edgewood Management LLC, Levin Capital Strategies L.P., Investec Asset Management LTD, Orbimed Advisors LLC, I.G. Investment Management LTD., Fred Alger Management Inc. and Janus Capital Management LLC. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, State Street Corp, Asset Management One Co. Ltd., Numeric Investors LLC, FIL Ltd, Russell Investments Group Ltd., Elkfork Partners LLC and Prudential PLC.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Gilead Sciences stock cost?

One share of Gilead Sciences stock can currently be purchased for approximately $70.48.

Gilead Sciences (NASDAQ:GILD) Chart for Wednesday, March, 1, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Earnings History Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History Chart

Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Last Updated on 3/1/2017 by Staff